NEXGEL, INC.

NEXGEL, INC. is an innovative medical device company specializing in the development and commercialization of proprietary hydrogel-based products. Founded in 2004 and headquartered in Langhorne, Pennsylvania, the company's mission is to become a leader in hydrogel technology solutions, extending its applications beyond healthcare into new consumer markets. It aims to deliver innovative, effective, and user-friendly products while expanding the use of its ultra-gentle, high-water-content hydrogels.

NEXGEL operates as both a Contract Development and Manufacturing Organization (CDMO) and a branded consumer products company, leveraging its proprietary electron-beam cross-linked hydrogel technology. Its product portfolio includes advanced wound dressings like SilverSeal®, sterile ophthalmic shields, and consumer brands such as Medagel, Kenkoderm, and Silly George. The company also offers over-the-counter remedy solutions for blisters and pain, as well as various beauty and cosmetic applications. NEXGEL maintains a strategic market presence by collaborating with healthcare providers, distributors, and original equipment manufacturers (OEMs) to integrate its hydrogel technologies into existing and new medical products.

In recent news, NEXGEL appointed Ian Blackman as its Chief Financial Officer on April 27, 2026. A significant strategic move occurred in March 2026 when NEXGEL signed a definitive agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity Inc. This acquisition is anticipated to approximately triple NEXGEL's annual revenue and make the company profitable immediately upon closing, positioning it at the intersection of the OTC drugs, U.S. beauty and personal care, and U.S. healthcare markets. NEXGEL is positioned as a high-growth, niche player in the global hydrogel market, utilizing its proprietary technology for both high-margin contract manufacturing and the expansion of its consumer brand portfolio.